Table 1.
List of 35 FDA-approved combination immunotherapies as of May 10, 2022.
| FDA approval date | Tumor type | Combination agent |
|---|---|---|
| 10/01/2015 | BRAFWT metastatic melanoma | Nivolumab + Ipilimumab |
| 01/23/2016 | Metastatic melanoma across BRAF status | Nivolumab + Ipilimumab |
| 05/10/2017 | First-line metastatic NSCLC | Pembrolizumab + Pemetrexed + Carboplatin |
| 02/16/2018 | Stage III NSCLC | Durvalumab + Chemoradiation |
| 04/16/2018 | First-line intermediate or poor-risk advanced RCC | Nivolumab + Ipilimumab |
| 07/10/2018 | MSI-H or dMMR metastatic CRC | Nivolumab + Ipilimumab |
| 08/20/2018 | Metastatic nonsquamous NSCLC | Pembrolizumab + Pemetrexed + Chemotherapy |
| 10/30/2018 | First-line metastatic squamous NSCLC | Pembrolizumab + Chemotherapy |
| 12/06/2018 | First-line NSCLC | Atezolizumab + bevacizumab, paclitaxel and carboplatin |
| 03/08/2019 | Metastatic TNBC | Atezolizumab + Nabpaclitaxel |
| 03/18/2019 | Extensive-stage SCLC | Atezolizumab + Carboplatin + Etoposide |
| 04/19/2019 | First-line advanced RCC | Pembrolizumab + Axitinib |
| 05/14/2019 | First-line advanced RCC | Avelumab + Axitinib |
| 06/11/2019 | HNSCC | Pembrolizumab + Chemotherapy |
| 06/17/2019 | Metastatic SCLC | Pembrolizumab + Chemotherapy |
| 09/17/2019 | Advanced endometrial carcinoma | Pembrolizumab + Lenvatinib |
| 12/03/2019 | First-line Metastatic NSCLC without EGFR/ALK aberrations | Atezolizumab + Nab-paclitaxel + Carboplatin |
| 03/10/2020 | Advanced HCC after sorafenib | Nivolumab + Ipilimumab |
| 03/27/2020 | Extensive-stage SCLC | Durvalumab + Etoposide + either Carboplatin or Cisplatin |
| 05/15/2020 | First-line mNSCLC (PD-L1 tumor expression ≥1%) | Nivolumab + Ipilimumab |
| 05/26/2020 | First-line Metastatic NSCLC | Nivolumab + Ipilimumab +2 cycles of platinum-doublet chemotherapy |
| 05/29/2020 | First-line unresectable HCC | Atezolizumab + Bevacizumab |
| 06/30/2020 | Locally advanced or metastatic urothelial carcinoma | Avelumab + Chemotherapy |
| 07/30/2020 | BRAF V600 unresectable or metastatic melanoma | Atezolizumab + Cobimetinib + Vemurafenib |
| 10/02/2020 | First-line malignant pleural mesothelioma | Nivolumab + Ipilimumab |
| 11/13/2020 | Locally recurrent unresectable or metastatic TNBC | Pembrolizumab + Chemotherapy |
| 01/22/2021 | First-line advanced RCC | Nivolumab + Cabozantinib |
| 03/22/2021 | Esophageal or GEJ carcinoma | Pembrolizumab + Chemotherapy |
| 04/16/2021 | Metastatic gastric cancer and esophageal adenocarcinoma | Nivolumab + fluoropyrimidine- and platinum-containing chemotherapy |
| 05/05/2021 | First-line HER2-positive gastric cancer | Pembrolizumab + Trastuzumab + Chemotherapy |
| 07/21/2021 | Advanced endometrial carcinoma | Pembrolizumab + Lenvatinib |
| 07/26/2021 | High-risk early-stage TNBC | Pembrolizumab + Chemotherapy |
| 08/10/2021 | First-line advanced RCC | Pembrolizumab + Lenvatinib |
| 10/13/2021 03/04/2022 |
First-line cervical cancer Neoadjuvant resectable NSCLC |
Pembrolizumab + Chemotherapy ± Bevacizumab Nivolumab + Chemotherapy |
Note: Dates are listed as month/day/year. GEJ: gastroesophageal junction; HNSCC: head and neck squamous cell carcinoma; SCLC: small cell lung cancer; TNBC: triple negative breast cancer. Source: https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancer-hematologic-malignancies-approval-notifications.
Dates are listed as month/day/year. CRC: colorectal cancer; GEJ: gastroesophageal junction; HNSCC: head and neck squamous cell carcinoma; NSCLC: non-small cell lung cancer. SCLC: small cell lung cancer; TNBC: triple negative breast cancer.